Key facts
- It has raised $6.3M across 3 recorded rounds; the latest was Early Stage VC ($13.2M) in Feb 2026.
- Notable investors include Gates Foundation.
- Inflammasome Therapeutics has filed 3 Form Ds with the SEC since 2023, most recently Mar 2025 ($2.5M sold to 27 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Inflammasome Therapeutics
Funding rounds
3 roundsAbout Inflammasome Therapeutics
Developer of therapies designed to focus on prevalent, degenerative diseases such as Alzheimer's and multiple sclerosis. The company's products are effective against diseases characterized by upregulation of the inflammatory process, driven by prolonged activation of cytosolic multiprotein complexes, enabling patients to reduce and prevent aberrant inflammasome activation.
- Sector
- Healthcare
- HQ
- Newton, MA, United States
- Founded
- 2016
- Website
- inflam.com/
- Ownership
- Privately Held (backing)
Inflammasome Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inflammasome Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inflammasome Therapeutics in its N-PORT filings yet. We sweep new filings monthly.